3-Hydroxy-8,9-methylenedioxypterocarpeneCAS# 59901-98-3 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 59901-98-3 | SDF | Download SDF |
| PubChem ID | 14730797 | Appearance | Powder |
| Formula | C16H10O5 | M.Wt | 282.3 |
| Type of Compound | Phenols | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| SMILES | C1C2=C(C3=C(O1)C=C(C=C3)O)OC4=CC5=C(C=C24)OCO5 | ||
| Standard InChIKey | XCDMHEXDCIXKLK-UHFFFAOYSA-N | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
3-Hydroxy-8,9-methylenedioxypterocarpene Dilution Calculator
3-Hydroxy-8,9-methylenedioxypterocarpene Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.5423 mL | 17.7117 mL | 35.4233 mL | 70.8466 mL | 88.5583 mL |
| 5 mM | 0.7085 mL | 3.5423 mL | 7.0847 mL | 14.1693 mL | 17.7117 mL |
| 10 mM | 0.3542 mL | 1.7712 mL | 3.5423 mL | 7.0847 mL | 8.8558 mL |
| 50 mM | 0.0708 mL | 0.3542 mL | 0.7085 mL | 1.4169 mL | 1.7712 mL |
| 100 mM | 0.0354 mL | 0.1771 mL | 0.3542 mL | 0.7085 mL | 0.8856 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Sulfasalazine
Catalog No.:BCC2545
CAS No.:599-79-1
- 3,3'-Sulfonyldianiline
Catalog No.:BCC8595
CAS No.:599-61-1
- Medicagenic acid
Catalog No.:BCN3893
CAS No.:599-07-5
- Mesopsin
Catalog No.:BCN8050
CAS No.:5989-16-2
- Loliolid
Catalog No.:BCN3655
CAS No.:5989-02-6
- 7-hydroxy-4-benzopyrone
Catalog No.:BCC9209
CAS No.:59887-89-7
- ent-7alpha,9-Dihydroxy-15-oxokaur-16-en-19,6bet-olide
Catalog No.:BCN7401
CAS No.:59885-89-1
- N-Formyl-Met-Leu-Phe
Catalog No.:BCC7205
CAS No.:59880-97-6
- L-Dihydroorotic acid
Catalog No.:BCC9007
CAS No.:5988-19-2
- Glabridin
Catalog No.:BCN1221
CAS No.:59870-68-7
- Oxybuprocaine HCl
Catalog No.:BCC4691
CAS No.:5987-82-6
- Cyclosporin A
Catalog No.:BCC4773
CAS No.:59865-13-3
- Vicenin -3
Catalog No.:BCN3014
CAS No.:59914-91-9
- HPI 1
Catalog No.:BCC3938
CAS No.:599150-20-6
- Vindesine sulfate
Catalog No.:BCC8266
CAS No.:59917-39-4
- Vicriviroc maleate
Catalog No.:BCC2038
CAS No.:599179-03-0
- 3',4'-dihydro-3'-hydroxy-Xanthyletin
Catalog No.:BCN3680
CAS No.:5993-18-0
- Malotilate
Catalog No.:BCC1196
CAS No.:59937-28-9
- Carlinoside
Catalog No.:BCN2853
CAS No.:59952-97-5
- Tagitinin F
Catalog No.:BCN4101
CAS No.:59979-57-6
- Tagitinin A
Catalog No.:BCN4102
CAS No.:59979-61-2
- EDTA
Catalog No.:BCC7493
CAS No.:60-00-4
- Guanethidine Sulfate
Catalog No.:BCC3789
CAS No.:60-02-6
- H-Tyr-OH
Catalog No.:BCC3123
CAS No.:60-18-4
Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carbox ylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.[Pubmed:20718494]
J Med Chem. 2010 Aug 26;53(16):6003-17.
Previously, we reported the discovery of PSI-697 (1a), a C-2 benzyl substituted quinoline salicylic acid-based P-selectin inhibitor. It is active in a variety of animal models of cardiovascular disease. Compound 1a has also been shown to be well tolerated and safe in healthy volunteers at doses of up to 1200 mg in a phase 1 single ascending dose study. However, its oral bioavailability was low. Our goal was to identify a back up compound with equal potency, increased solubility, and increased exposure. We expanded our structure-activity studies in this series by branching at the alpha position of the C-2 benzyl side chain and through modification of substituents on the carboxylic A-ring of the quinoline. This resulted in discovery of PSI-421 with marked improvement in aqueous solubility and pharmacokinetic properties. This compound has shown oral efficacy in animal models of arterial and venous injury and was selected as a preclinical development compound for potential treatment of such diseases as atherosclerosis and deep vein thrombosis.
Structure of (+/-)-(1S*,3S*)-3-hydroxy-8,11,11-trimethyl-9-oxobicyclo[5.3.1]undec-7- en-1-yl benzoate.[Pubmed:2222934]
Acta Crystallogr C. 1990 Jul 15;46 ( Pt 7):1353-5.
C21H26O4, Mr = 342.43, monoclinic, P2(1)/n, a = 7.211 (2), b = 19.521 (6), c = 12.674 (3) A, beta = 95.04 (2) degrees, V = 1777.2 (8) A3, Z = 4, Dx = 1.28 g cm-3, Mo K alpha radiation, lambda = 0.7107 A, mu = 0.8152 cm-1, F(000) = 736, T = 163 K, R = 0.0632 for 3754 reflections [Fo greater than or equal to 4 sigma(Fo)]. The molecules exist as hydrogen-bonded dimers [O14-H14...O16 (related by -x, 1-y, 1-z), O14...O16 2.775 (2), H14...O16 1.93 (2) A, O14-H14...O16 175 (2) degrees] which stack in columns along b. Distortion at the bridgehead double bond is observed. Deviations from ideal values for the torsion angles around the double bond, C7-C8, are as large as 17.8 (2) degrees. The dihedral angle between planes through C6-C7-C8-C11 and C7-C8-C9-C15, the planar portions of the alkene moiety, is 13.4 (9) degrees. The Csp2--Csp3 bond lengths involving C7 are asymmetric with C7-C6 1.501 (2) and C7-C11 1.538 (2) A. The bond length C7-C8 is elongated [1.352 (3) A] for a C-C double bond. The enone system is also non-planar [max. deviation -0.404 (2) A for C10].
